Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of cabozantinib and vandetinib in medullary thyroid cancer.
Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of cabozantinib and vandetinib in medullary thyroid cancer.
Cabozantinib and vandetinib are both approved agents and work through similar mechanisms, as tyrosine kinase inhibitors of RET. Though these drugs target RET, which is important in medullary thyroid cancer, they also target VEGFR, EGFR, and MET.
Cabozantinib and vandetinib both showed benefit to progression-free survival in phase III trial vs placebo. The problem with medullary thyroid cancer, Sherman says, is that it is a slow-growing disease and can be treated with many other drugs. It is unknown if either drug can demonstrate true benefit to overall survival or quality of life.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More